Ontology highlight
ABSTRACT:
SUBMITTER: Goker Bagca B
PROVIDER: S-EPMC7305753 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature
Cytokine & growth factor reviews 20200620
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potent ...[more]